These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1027 related articles for article (PubMed ID: 10458611)

  • 1. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene.
    Lin L; Faraco J; Li R; Kadotani H; Rogers W; Lin X; Qiu X; de Jong PJ; Nishino S; Mignot E
    Cell; 1999 Aug; 98(3):365-76. PubMed ID: 10458611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines.
    Hungs M; Fan J; Lin L; Lin X; Maki RA; Mignot E
    Genome Res; 2001 Apr; 11(4):531-9. PubMed ID: 11282968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sleep, sleep disorders and hypocretin (orexin).
    Mignot E
    Sleep Med; 2004 Jun; 5 Suppl 1():S2-8. PubMed ID: 15301991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. I. Mutation in the hypocretin (orexin) receptor 2 gene causes canine narcolepsy.
    Reilly CE
    J Neurol; 1999 Oct; 246(10):985-6. PubMed ID: 10552257
    [No Abstract]   [Full Text] [Related]  

  • 5. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.
    Chemelli RM; Willie JT; Sinton CM; Elmquist JK; Scammell T; Lee C; Richardson JA; Williams SC; Xiong Y; Kisanuki Y; Fitch TE; Nakazato M; Hammer RE; Saper CB; Yanagisawa M
    Cell; 1999 Aug; 98(4):437-51. PubMed ID: 10481909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DLA-DQB1 alleles and bone marrow transplantation experiments in narcoleptic dogs.
    Wagner JL; Storb R; Storer B; Mignot E
    Tissue Antigens; 2000 Sep; 56(3):223-31. PubMed ID: 11034558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes.
    Willie JT; Chemelli RM; Sinton CM; Tokita S; Williams SC; Kisanuki YY; Marcus JN; Lee C; Elmquist JK; Kohlmeier KA; Leonard CS; Richardson JA; Hammer RE; Yanagisawa M
    Neuron; 2003 Jun; 38(5):715-30. PubMed ID: 12797957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and neurobiological aspects of narcolepsy.
    Nishino S
    Sleep Med; 2007 Jun; 8(4):373-99. PubMed ID: 17470414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic studies in narcolepsy, a disorder affecting REM sleep.
    Faraco J; Lin X; Li R; Hinton L; Lin L; Mignot E
    J Hered; 1999; 90(1):129-32. PubMed ID: 9987919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Narcolepsy genes wake up the sleep field.
    Takahashi JS
    Science; 1999 Sep; 285(5436):2076-7. PubMed ID: 10523205
    [No Abstract]   [Full Text] [Related]  

  • 11. Animal models of narcolepsy.
    Chen L; Brown RE; McKenna JT; McCarley RW
    CNS Neurol Disord Drug Targets; 2009 Aug; 8(4):296-308. PubMed ID: 19689311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy.
    Mishima K; Fujiki N; Yoshida Y; Sakurai T; Honda M; Mignot E; Nishino S
    Sleep; 2008 Aug; 31(8):1119-26. PubMed ID: 18714784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog.
    Fujiki N; Yoshida Y; Ripley B; Mignot E; Nishino S
    Sleep; 2003 Dec; 26(8):953-9. PubMed ID: 14746374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypocretin/orexin, sleep and narcolepsy.
    Hungs M; Mignot E
    Bioessays; 2001 May; 23(5):397-408. PubMed ID: 11340621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems.
    Mignot E; Nishino S; Sharp LH; Arrigoni J; Siegel JM; Reid MS; Edgar DM; Ciaranello RD; Dement WC
    J Neurosci; 1993 Mar; 13(3):1057-64. PubMed ID: 8095066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Narcolepsy and the hypocretins.
    Wurtman RJ
    Metabolism; 2006 Oct; 55(10 Suppl 2):S36-9. PubMed ID: 16979425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hypocretin/orexin system in health and disease.
    Nishino S
    Biol Psychiatry; 2003 Jul; 54(2):87-95. PubMed ID: 12873797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Narcolepsy: a key role for hypocretins (orexins).
    Siegel JM
    Cell; 1999 Aug; 98(4):409-12. PubMed ID: 10481905
    [No Abstract]   [Full Text] [Related]  

  • 19. Narcolepsy without cataplexy: 2 subtypes based on CSF hypocretin-1/orexin-A findings.
    Oka Y; Inoue Y; Kanbayashi T; Kuroda K; Miyamoto M; Miyamoto T; Ikeda A; Shimizu T; Hishikawa Y; Shibasaki H
    Sleep; 2006 Nov; 29(11):1439-43. PubMed ID: 17162990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system.
    Nishino S; Kanbayashi T
    Sleep Med Rev; 2005 Aug; 9(4):269-310. PubMed ID: 16006155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.